Quick Answer
Immunome Inc. reported Total Assets of $683.19 million for fiscal year 2025.
Immunome Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $683.19M | +184.4% |
| 2024 | $240.24M | +61.7% |
| 2023 | $148.54M | +517.7% |
| 2022 | $24.05M | -58.5% |
| 2021 | $57.92M | +30.1% |
| 2020 | $44.52M | +779.9% |
| 2019 | $5.06M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $299.38M | +16.5% | +1.0% |
| June 30, 2025 | $296.29M | +0.0% | -13.5% |
| March 31, 2025 | $342.69M | +7.2% | +42.6% |
| December 31, 2024 | $240.24M | +61.7% | -6.5% |
| September 30, 2024 | $256.90M | +175.8% | -13.3% |
| June 30, 2024 | $296.21M | +614.9% | -7.4% |
| March 31, 2024 | $319.75M | +564.6% | +115.3% |
| December 31, 2023 | $148.54M | +517.7% | +59.4% |
- Immunome Inc. showed an increase of +184.4% in Total Assets compared to the prior fiscal year.
- Over the 2019–2025 period, Immunome Inc.’s total assets has grown by 13401.7% (from $5.06 million to $683.19 million).
- The most recent figure is from Immunome Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: